Pfizer reports positive results for Talzenna/Xtandi combo

Pfizer (NYSE:PFE) reported positive results from a Phase 3 study of its drug Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer.

The study, called TALAPRO-3, showed the combination demonstrated a statistically significant and clinically meaningful improvement